Shenzhen New Industries Biomedical Engineering (300832) Q2 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 was ¥2.18 billion, down 1.18% year-over-year; net profit attributable to shareholders was ¥771 million, down 14.62% year-over-year.

• Domestic business faced pressure from centralized procurement and payment reforms, leading to a 12.81% decline in domestic revenue, while overseas revenue grew 19.57%.

• Gross margin was 68.64%, with instrument margin at 26.16% and reagent margin at 87.08%.

• The company continued to invest in R&D, launching new high-end instruments and expanding its product pipeline.

Financial highlights

• Operating income: ¥2,184,828,547.37, down 1.18% year-over-year.

• Net profit attributable to shareholders: ¥771,072,535.19, down 14.62% year-over-year.

• Operating cash flow: ¥461,456,489.11, down 25.39% year-over-year.

• Basic and diluted EPS: ¥0.9814, down 14.62% year-over-year.

• Total assets at period end: ¥8,983,627,781.48, down 6.61% from year-end 2024.

Outlook and guidance

• The company will focus on high-value clinical diagnostic projects and adapt to ongoing healthcare reforms and procurement policies.

• Continued global expansion and product innovation are expected to drive future growth.